# A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

> clinical trial · VERIFIED · 2026-06-22

Status: ACTIVE_NOT_RECRUITING · Sponsor: Fred Hutchinson Cancer Center · Condition: Recurrent B-Cell Non-Hodgkin Lymphoma

- Company: Fred Hutchinson Cancer Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT03277729

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.